Pfizer (PFE) : Ssi Investment Management Inc reduced its stake in Pfizer by 0.02% during the most recent quarter end. The investment management company now holds a total of 24,441 shares of Pfizer which is valued at $811,197 after selling 5 shares in Pfizer , the firm said in a disclosure report filed with the SEC on May 9, 2016.Pfizer makes up approximately 0.25% of Ssi Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Evanson Asset Management boosted its stake in PFE in the latest quarter, The investment management firm added 194 additional shares and now holds a total of 13,635 shares of Pfizer which is valued at $452,546. Pfizer makes up approx 0.15% of Evanson Asset Management’s portfolio.Ausdal Financial Partners boosted its stake in PFE in the latest quarter, The investment management firm added 1,278 additional shares and now holds a total of 13,163 shares of Pfizer which is valued at $442,014. Pfizer makes up approx 0.25% of Ausdal Financial Partners’s portfolio.Chase Investment Counsel Corp boosted its stake in PFE in the latest quarter, The investment management firm added 890 additional shares and now holds a total of 9,475 shares of Pfizer which is valued at $318,171. Pfizer makes up approx 0.14% of Chase Investment Counsel Corp’s portfolio.Moody Lynn Lieberson boosted its stake in PFE in the latest quarter, The investment management firm added 257 additional shares and now holds a total of 53,205 shares of Pfizer which is valued at $1,786,624. Pfizer makes up approx 0.28% of Moody Lynn Lieberson’s portfolio.Chicago Partners Investment Group reduced its stake in PFE by selling 3,950 shares or 34.38% in the most recent quarter. The Hedge Fund company now holds 7,540 shares of PFE which is valued at $246,633. Pfizer makes up approx 0.12% of Chicago Partners Investment Group’s portfolio.
Pfizer (PFE) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $33.33 and reached the intraday high at $33.45. The bulls started the profit booking and pushed the shares to intraday low of $33.135. The trading session was marked by a volume range of 2,05,14,662 shares exchanging hands. The 52-week high of the shares is $36.46 and the 52-week low is $28.25. The market cap of the company stands at $201,292 M and there are 6,06,48,49,400 shares in public circulation.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Pfizer. Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.